Aptabio Receives Approval for Phase 2 Clinical Trial Plan of Diabetic Nephropathy Treatment in Europe
[Asia Economy Reporter Minji Lee] Aptabio announced on the 20th that it has received approval for the Investigational New Drug (IND) application for the Phase 2 clinical trial of APX-115, a treatment for diabetic nephropathy, in Europe.
Hot Picks Today
"Do We Need to Panic Buy Again?" War Drives 30% Price Surge... Even the Bedroom Feels the Impact
- "Suspicious Timing?"...Trump Traded Stocks After Praising Wartime Capabilities
- There Is a Distinct Age When Physical Abilities Decline Rapidly... From What Age Do Strength and Endurance Drop?
- "Anyone Who Visited the Room Salon, Come Forward"… Gangnam Police Station Launches Full Staff Investigation After New Scandal
- "Contact Me First If Houses Are Built": Wealthy Clients Eyeing... Will Ultra-High-End Residences Worth 20 Billion Won Be Developed? [Real Estate AtoZ]
The company stated, "The purpose is to evaluate the safety and therapeutic efficacy of APX-115 in patients with diabetic nephropathy," adding, "Currently, there are no drugs approved as specialized treatments for diabetic nephropathy, so there is a significant demand for the development of new treatments for diabetic nephropathy."
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
